Horizon Pharma plc to Participate in BMO Prescriptions for Success Healthcare Conference
November 30, 2017 16:05 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
November 30, 2017 06:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc Selected as One of Chicago’s Top Workplaces by the Chicago Tribune
November 10, 2017 09:30 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 07, 2017 16:05 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout
November 06, 2017 12:00 ET
|
Horizon Pharma plc
-- Initial data from investigator-initiated TRIPLE study shows infusion reactions occurred in less than 1 percent of infusions -- -- Analyses further support the efficacy and safety of KRYSTEXXA -- ...
Horizon Pharma plc Announces Third-Quarter and Year-to-Date 2017 Results
November 06, 2017 07:00 ET
|
Horizon Pharma plc
-- Third-Quarter 2017 Net Sales of $271.6 Million -- -- Third-Quarter 2017 Net Loss of $64.0 Million; Adjusted EBITDA of $108.1 Million -- -- Third-Quarter 2017 GAAP Operating Cash Flow of $68.3...
Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age
November 04, 2017 11:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 04, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017
November 03, 2017 11:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc to Participate in Investor Conferences in November
November 02, 2017 16:05 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces Availability of PROCYSBI™ (cysteamine bitartrate) in Canada
October 26, 2017 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...